Warren Whitehead
Directeur/Membre du Conseil chez APTOSE BIOSCIENCES INC.
Fortune : 1 160 $ au 30/04/2024
Postes actifs de Warren Whitehead
Sociétés | Poste | Début | Fin |
---|---|---|---|
APTOSE BIOSCIENCES INC. | Directeur/Membre du Conseil | 07/04/2011 | - |
Independent Dir/Board Member | 07/04/2011 | - | |
SATELLOS BIOSCIENCE INC. | Corporate Officer/Principal | 01/09/2023 | - |
Directeur Financier/CFO | 13/08/2021 | 01/09/2023 | |
St. Luke's Episcopal Hospital
St. Luke's Episcopal Hospital Hospital/Nursing ManagementHealth Services St. Luke's Episcopal Hospital provides medical and healthcare services. Its services include home health care, outpatient, surgical, cancer care, pulmonary care, rehabilitation therapy, and other health care services. The company was founded in 1954 and is headquartered in Houston, TX | Corporate Officer/Principal | - | - |
Resolution Pharmaceuticals, Inc. | Directeur Financier/CFO | - | - |
Historique de carrière de Warren Whitehead
Anciens postes connus de Warren Whitehead
Sociétés | Poste | Début | Fin |
---|---|---|---|
TELESTA THERAPEUTICS INC | Directeur/Membre du Conseil | - | 01/01/2016 |
Independent Dir/Board Member | - | 01/01/2016 | |
PROMIS NEUROSCIENCES, INC. | Directeur/Membre du Conseil | 04/09/2014 | 15/08/2015 |
Directeur Financier/CFO | 01/02/2013 | 15/08/2015 | |
Arius Research, Inc.
Arius Research, Inc. BiotechnologyHealth Technology Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada. | Directeur Financier/CFO | 01/01/2006 | - |
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | Directeur Financier/CFO | 01/01/2000 | 01/01/2006 |
Satellos Bioscience, Inc. /Old/
Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Directeur Financier/CFO | 13/08/2021 | - |
░░░░░░░░░ ░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░ ░░░░░ | ░░░░░░░░ | - | - |
░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Formation de Warren Whitehead
University of Western Ontario | Undergraduate Degree |
University of Windsor | Masters Business Admin |
Statistiques
Internationale
Canada | 13 |
Etats-Unis | 2 |
2 |
Opérationnelle
Director of Finance/CFO | 6 |
Corporate Officer/Principal | 3 |
Director/Board Member | 3 |
Sectorielle
Health Technology | 10 |
Consumer Services | 3 |
Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
APTOSE BIOSCIENCES INC. | Health Technology |
PROMIS NEUROSCIENCES, INC. | Health Technology |
STAGEZERO LIFE SCIENCES LTD. | Health Technology |
Entreprise privées | 9 |
---|---|
Telesta Therapeutics, Inc.
Telesta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Telesta Therapeutics, Inc. is a biotechnology company, which focuses on the licensing/acquisition and development of transformational therapeutics for the treatment of serious human diseases, such as cancer, immune diseases, and targeted rare diseases. The company was founded by Graeme McRae in 1979 and is headquartered in Pointe-Claire, Canada. | Health Technology |
Arius Research, Inc.
Arius Research, Inc. BiotechnologyHealth Technology Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada. | Health Technology |
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | Health Technology |
St. Luke's Episcopal Hospital
St. Luke's Episcopal Hospital Hospital/Nursing ManagementHealth Services St. Luke's Episcopal Hospital provides medical and healthcare services. Its services include home health care, outpatient, surgical, cancer care, pulmonary care, rehabilitation therapy, and other health care services. The company was founded in 1954 and is headquartered in Houston, TX | Health Services |
GlaxoSmithKline, Inc.
GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Health Technology |
Resolution Pharmaceuticals, Inc. | |
PlantForm Corp.
PlantForm Corp. Pharmaceuticals: MajorHealth Technology PlantForm Corp. engages in a biopharmaceutical company. It focuses on the development and production of ntibody and protein drugs using manufacturing platform. The firm’s vivoXPRESS technology uses genetically modified tobacco plants to produce biopharmaceuticals in fully contained greenhouse environments. The company was founded by J. Christopher Hall, Mark Goldberg, Don Stewart, and Ronald G. Hosking in 2008 and is headquartered in Toronto, Canada. | Health Technology |
Satellos Bioscience, Inc. /Old/
Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Health Technology |
Satellos Bioscience, Inc. |
- Bourse
- Insiders
- Warren Whitehead
- Expérience